Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 1.00 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.91 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.91 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.91 |
| ▸ | NSD2 | O96028 | 1/20 | 0.91 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.91 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.91 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.91 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.91 |
| ▸ | BID | P55957 | 1/20 | 0.91 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.91 |
| ▸ | ASPH | Q12797 | 1/20 | 0.91 |
| ▸ | BAD | Q92934 | 1/20 | 0.91 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.91 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.91 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699927 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1699923 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1699925 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL16160643 | 1.00 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1700482 | 0.96 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1700822 | 0.96 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL30314018 | 0.96 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1700486 | 0.96 | BCL2 (1.00) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL1700287 | 0.96 | BCL2 (0.92) | BCL2BCL2L1MCL1BCL2L2NSD2 | |
| SCHEMBL30314129 | 0.96 | BCL2 (0.92) | BCL2BCL2L1MCL1BCL2L2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220380476-A1 | Use of an anti-CCR7 antibody in combination therapies with a BTK inhibitor and/or BCL2- inhibitor for treating hematological malignancies | CATAPULT THERAPEUTICS B.V. (NL) | 2022-12-01 | — | — | US | disclosed |
| EP-4041764-A1 | USE OF AN ANTI-CCR7 ANTIBODY IN COMBINATION THERAPIES WITH A BTK INHIBITOR AND/OR BCL2- INHIBITOR FOR TREATING HEMATOLOGICAL MALIGNANCIES | Catapult Therapeutics B.V. (NL) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885MCL1 13/4885 |
| US-20220380476-A1 | Use of an anti-CCR7 antibody in combination therapies with a BTK inhibitor and/or BCL2- inhibitor for treating hematological malignancies | BCL9, CCR7, BCL6B | BCL2 10/4885BCL2L1 8/4885MCL1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.